Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sunshine Biopharma (SBFM) EBITDA Margin: 2012-2024

Historic EBITDA Margin for Sunshine Biopharma (SBFM) over the last 11 years, with Dec 2024 value amounting to -19.10%.

  • Sunshine Biopharma's EBITDA Margin fell 1167.00% to -15.77% in Q3 2025 from the same period last year, while for Sep 2025 it was -17.37%, marking a year-over-year decrease of 444.00%. This contributed to the annual value of -19.10% for FY2024, which is 261.00% down from last year.
  • Sunshine Biopharma's EBITDA Margin amounted to -19.10% in FY2024, which was down 15.85% from -16.49% recorded in FY2023.
  • Sunshine Biopharma's 5-year EBITDA Margin high stood at -16.49% for FY2023, and its period low was -5,435.54% during FY2021.
  • Over the past 3 years, Sunshine Biopharma's median EBITDA Margin value was -19.10% (recorded in 2024), while the average stood at -215.59%.
  • Per our database at Business Quant, Sunshine Biopharma's EBITDA Margin plummeted by 153,732bps in 2021 and then spiked by 482,436bps in 2022.
  • Over the past 5 years, Sunshine Biopharma's EBITDA Margin (Yearly) stood at -3,898.21% in 2020, then crashed by 153,732bps to -5,435.54% in 2021, then skyrocketed by 482,436bps to -611.18% in 2022, then surged by 59,469bps to -16.49% in 2023, then crashed by 261bps to -19.10% in 2024.